Implantation of c-mycERTAM immortalized human mesencephalic-derived clonal cell lines ameliorates behavior dysfunction in a rat model of Parkinson's disease

Stem Cells and Development

Volumn 18, Issue 2, 2009, Pages 307-319

  Miljan, Erik A ^a   Hines, Susan J ^a   Pande, Priyadarshini ^a   Corteling, Randolph L ^a   Hicks, Caroline ^a   Zbarsky, Virginia ^a   Umachandran, Meera ^a   Sowinski, Peter ^a   Richardson, Sheila ^a   Tang, Ellen ^a   Wieruszew, Malgorzata ^a   Patel, Sara ^a   Stroemer, Paul ^a   Sinden, John D ^a  

^a RENEURON LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; BRAIN DERIVED NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR BETA SUBUNIT; NESTIN; OXIDOPAMINE; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL RESEARCH; BRAIN DAMAGE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL IMMORTALIZATION; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; FETUS; GROWTH REGULATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; KARYOTYPE; MESENCEPHALON; NERVE CELL; NERVE CELL MEMBRANE POTENTIAL; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; THERAPY EFFECT; TISSUE SECTION; TRANSGENE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL SURVIVAL; CLONE CELLS; DISEASE MODELS, ANIMAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCEPHALON; NEURONS; PARKINSON DISEASE; PROSTHESIS IMPLANTATION; PROTO-ONCOGENE PROTEINS C-MYC; RATS; ROTAROD PERFORMANCE TEST; TAMOXIFEN; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 62549151810     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2008.0078     Document Type: Article

References (42)

1. Lindvall O and P Hagell. (2002). Role of cell therapy in Parkinson disease. Neurosurg Focus 13:e2.
2. Mendez I, R Sanchez-Pernaute, O Cooper, A Vinuela, D Ferrari, L Bjorklund, A Dagher and O Isacson. (2005). Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128:1498-1510.
3. Lindvall O, P Brundin, H Widner, S Rehncrona, B Gustavii, R Frackowiak, KL Leenders, G Sawle, JC Rothwell, CD Marsden, et al. (1990). Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247:574-577.
4. Lindvall O, G Sawle, H Widner, JC Rothwell, A Bjorklund, D Brooks, P Brundin, R Frackowiak, CD Marsden, P Odin, et al. (1994). Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35:172-180.
5. Peschanski M, G Defer, JP N'Guyen, F Ricolfi, JC Monfort, P Remy, C Geny, Y Samson, P Hantraye, R Jeny, et al. (1994). Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117(Pt 3):487-499.
6. Hauser RA, TB Freeman, BJ Snow, M Nauert, L Gauger, JH Kordower and CW Olanow. (1999). Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56:179-187.
7. Piccini P, O Lindvall, A Bjorklund, P Brundin, P Hagell, R Ceravolo, W Oertel, N Quinn, M Samuel, S Rehncrona, H Widner and DJ Brooks. (2000). Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 48:689-695.
8. Mendez I, A Dagher, M Hong, P Gaudet, S Weerasinghe, V McAlister, D King, J Desrosiers, S Darvesh, T Acorn and H Robertson. (2002). Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg 96:589-596.
9. Piccini P, DJ Brooks, A Bjorklund, RN Gunn, PM Grasby, O Rimoldi, P Brundin, P Hagell, S Rehncrona, H Widner and O Lindvall. (1999). Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2:1137-1140.
10. Wenning GK, P Odin, P Morrish, S Rehncrona, H Widner, P Brundin, JC Rothwell, R Brown, B Gustavii, P Hagell, M Jahanshahi, G Sawle, A Bjorklund, DJ Brooks, CD Marsden, NP Quinn and O Lindvall. (1997). Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42:95-107.
11. Freed CR, PE Greene, RE Breeze, WY Tsai, W DuMouchel, R Kao, S Dillon, H Winfield, S Culver, JQ Trojanowski, D Eidelberg and S Fahn. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719.
12. Olanow CW, CG Goetz, JH Kordower, AJ Stoessl, V Sossi, MF Brin, KM Shannon, GM Nauert, DP Perl, J Godbold and TB Freeman. (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414.
13. Perrier AL, V Tabar, T Barberi, ME Rubio, J Bruses, N Topf, NL Harrison and L Studer. (2004). Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 101:12543-12548.
14. Ben-Hur T, M Idelson, H Khaner, M Pera, E Reinhartz, A Itzik and BE Reubinoff. (2004). Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 22:1246-1255.
15. Wang X, Y Lu, H Zhang, K Wang, Q He, Y Wang, X Liu, L Li and X Wang. (2004). Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease. Int J Dev Neurosci 22:175-183.
16. Schwarz SC, J Wittlinger, R Schober, A Storch and J Schwarz. (2006). Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with cyclosporine A. Parkinsonism Relat Disord 12:302-308.
17. Yasuhara T, N Matsukawa, K Hara, G Yu, L Xu, M Maki, SU Kim and CV Borlongan. (2006). Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J Neurosci 26:12497-12511.
18. Redmond DE, Jr, KB Bjugstad, YD Teng, V Ourednik, J Ourednik, DR Wakeman, XH Parsons, R Gonzalez, BC Blanchard, SU Kim, Z Gu, SA Lipton, EA Markakis, RH Roth, JD Elsworth, JR Sladek, Jr, RL Sidman and EY Snyder. (2007). Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci USA 104:12175-12180.
19. Pollock K, P Stroemer, S Patel, L Stevanato, A Hope, E Miljan, Z Dong, H Hodges, J Price and JD Sinden. (2006). A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol 199:143-155.
20. Donato R, EA Miljan, SJ Hines, S Aouabdi, K Pollock, S Patel, FA Edwards and JD Sinden. (2007). Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci 8:36.
21. Cosset FL, Y Takeuchi, JL Battini, RA Weiss and MK Collins. (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69:7430-7436.
22. Gonzalez D, O Miyamoto, T Touge, K Sumitani, S Kuriyama and T Itano. (2006). Unilateral ibotenic acid lesions of the prefrontal cortex reduce rotational behavior in 6-hydroxydopamine-lesioned rats. Acta Med Okayama 60:319-324.
23. Paxinos G and C Watson (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney, Orlando.
24. Baker KA, D Sadi, M Hong and I Mendez. (2000). Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft. J Comp Neurol 426:106-116.
25. Mukhida K, KA Baker, D Sadi and I Mendez. (2001). Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants. J Neurosci 21:3521-3530.
26. Deumens R, A Blokland and J Prickaerts. (2002). Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317.
27. Schallert T. (2006). Behavioral tests for preclinical intervention assessment. NeuroRx 3:497-504.
28. Modo M, RP Stroemer, E Tang, T Veizovic, P Sowinski and H Hodges. (2000). Neurological sequelae and long-term behavioural assessment of rats with transient middle cerebral artery occlusion. J Neurosci Methods 104:99-109.
29. Roberts TJ, J Price, SC Williams and M Modo. (2006). Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience 139:1187-1199.
30. Kim SU. (2007). Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev 29: 193-201.
31. Lendahl U, LB Zimmerman and RD McKay. (1990). CNS stem cells express a new class of intermediate filament protein. Cell 60:585-595.
32. Villa A, B Navarro-Galve, C Bueno, S Franco, MA Blasco and A Martinez-Serrano. (2004). Long-term molecular and cellular stability of human neural stem cell lines. Exp Cell Res 294:559-570.
33. Takahashi K and S Yamanaka. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
34. Takahashi K, K Tanabe, M Ohnuki, M Narita, T Ichisaka, K Tomoda and S Yamanaka. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.s
35. Knoepfler PS. (2008). Why Myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell 2:18-21.
36. Ourednik J, V Ourednik, WP Lynch, M Schachner and EY Snyder. (2002). Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 20:1103-1110.
37. Svendsen CN and JW Langston. (2004). Stem cells for Parkinson disease and ALS: replacement or protection? Nat Med 10:224-225.
38. Sabetrasekh R, YD Teng, J Ourednik, KI Park and EY Synder. (2006). Current views of the embryonic and neural stem cell: cell replacement or molecular repair. In: Cell Therapy, Stem Cells and Brain Repair. CD Sanberg and PR Sanberg, eds. Humana Press, Totowa, NJ, pp 1-30.
39. Lu P, LL Jones, EY Snyder and MH Tuszynski. (2003). Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol 181:115-129.
40. Fahn S and D Sulzer. (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1:139-154.
41. Pluchino S, L Zanotti, B Rossi, E Brambilla, L Ottoboni, G Salani, M Martinello, A Cattalini, A Bergami, R Furlan, G Comi, G Constantin and G Martino. (2005). Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436:266-271.
42. Martino G and S Pluchino. (2006). The therapeutic potential of neural stem cells. Nat Rev Neurosci 7:395-406.